fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

e-max.it: your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Eastbound Lane Restriction on I-24 Tennessee River Bridge Set for Thursday

KENTUCKY (5/26/15) — The Kentucky Transportation Cabinet plans to restrict eastbound traffic to one lane on the… Read More

UPDATE - MPD Seeks Three in Residential Robbery

MURRAY, Ky. (5/25/15) — According to a Murray Police Department report, MPD investigators, in cooperation with the… Read More
1 DOW 18,041.54
0.00 (0.00%)    
2 S&P 2,104.20
0.00 (0.00%)    
3 NASDAQ 5,032.75
0.00 (0.00%)    

Most Read This Week

May 22, 2015 7506

Madisonville Man Charged with First-Degree Rape

by SurfKY News
May 23, 2015 7212

Missing 5-Year-Old Boy Found

by Doreen Dennis, SurfKY News
May 20, 2015 3601

Pennyrile Forest State Resort Park Holding Beach…

by Gil Lawson
May 21, 2015 3372

Police Charge Madisonville Man with Harassing…

by SurfKY News
May 25, 2015 3334

Can Sunscreen Save Your Life?

by Melissa Patrick

Most Read This Month

May 15, 2015 10775

New Madisonville Business In Full Operation Soon

by Tammy Holloway, SurfKY News
May 15, 2015 7581

Investigation of Local Barber Shop Leads to Drug…

by SurfKY News

Stories Trending Now

May 25, 2015 3334

Can Sunscreen Save Your Life?

by Melissa Patrick
May 25, 2015 2270

Hopkins Man Injured in Muhlenberg Motorcycle…

by SurfKY News
May 26, 2015 1943

Mandarin House Gearing Up to Open Soon

by Gary Gates, SurfKY News
May 26, 2015 1938

Large Necklace on Rearview Mirror Lands Driver in…

by SurfKY News
May 25, 2015 1895

UPDATE - MPD Seeks Three in Residential Robbery

by SurfKY News
May 26, 2015 1669

Governor Announces Hopkins County as Kentucky…

by Doreen Dennis, SurfKY News
May 25, 2015 1239

Seniors Celebrate with Cook-out, Games, Fellowship

by Tammy Holloway, SurfKY News
May 25, 2015 1217

Damascus Road House Leads Young People to Christ

by Tammy Holloway, SurfKY News
May 26, 2015 1185

Two Central City People Jailed on Meth Charges

by SurfKY News
May 25, 2015 1056

‘Remembering Those That Paid All’

by Tammy Holloway, SurfKY News